Healing Livers, Saving Lives: Hepatitis C Screening in an Era of Cure

Courtney M. Boucher, Anne Walsh, Christopher Forest

Research output: Contribution to journalArticlepeer-review


Chronic hepatitis C affects more than 3 million people in the United States. In the past, drug therapy with interferon and ribavirin resulted in low overall cure rates and early discontinuation due to adverse reactions. The new direct-acting antivirals offer not only a shorter duration of treatment with fewer adverse reactions, but greatly improved overall cure rates as high as 96%. Updated national screening recommendations (including a one-time screening for patients born between 1945 and 1965), combined with timely referral and treatment, offer a prime opportunity for healthcare providers to improve public health outcomes and reduce healthcare costs.
Original languageAmerican English
JournalJournal of the American Academy of Physician Assistants
StatePublished - May 2016


  • hepatitis C
  • HCV
  • direct-acting antivirals
  • sofosbuvir
  • ledipasvir
  • screening


  • Medicine and Health Sciences

Cite this